Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News

Category Archives: Cancer Immunotherapy

30Mar/24

CD73 Inhibition: A Promising Strategy for Overcoming Immune Evasion in Colorectal Cancer

March 30, 2024Antibody Engineering R&D, Cancer ImmunotherapyColorectal Cancer, Targeting CD73biorab

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, with the likelihood of distant metastasis to the liver or lungs adding to the challenges of CRC treatment. Currently, surgical resectionRead More…

03Nov/23

Two New Strategies Targeting Siglec-7 Show Promise in Treating Ovarian Cancer

November 3, 2023Cancer Immunotherapy, Recombinant Antibody R&DOvarian Cancer, Siglec-7biorab

Ovarian cancer is often diagnosed in advanced stages, and its resistance to existing treatment methods poses a significant challenge. According to data from the National Institutes of Health (NIH) in the UnitedRead More…

05Oct/23

Researchers Revealed the Feasibility and Clinical Prospects of Targeting SLC7A11 for the Treatment of Osteosarcoma

October 5, 2023Cancer ImmunotherapyOsteosarcoma, SLC7A11biorab

Osteosarcoma (OS) is the most common malignant bone tumor, primarily affecting adolescents. In the 1970s, the clinical use of chemotherapy in conjunction with surgical resection significantly improved the five-year survival rate ofRead More…

01Aug/23

Scientists Identify Special Genes Capable of Producing a Large Number of Key Antibodies

August 1, 2023Cancer Immunotherapy, Therapeutic Antibody R&DAntibody Productionbiorab

Cellular secretions play various crucial roles within the body. However, methods to connect this functional information with surface markers and the transcriptome have been lacking. In a recent research paper published inRead More…

14Jul/23

Targeting Integrins for the Treatment of Drug-Resistant Acute Myeloid Leukemia

July 14, 2023Cancer ImmunotherapyAcute Myeloid Leukemia, Integrinbiorab

Acute myeloid leukemia (AML) remains highly resistant to treatment with a high relapse rate, necessitating the development of new therapeutic strategies. Integrin-targeted therapy, which has been extensively studied in solid tumors andRead More…

29Jun/23

The Roles of Loss of CXCR2 Expression/Activity in Melanoma Tumorigenesis

June 29, 2023Cancer ImmunotherapyCXCR2, Melanoma Tumorigenesisbiorab

Chemokines and their receptors have been shown to play crucial roles in regulating tumor growth, progression, metastasis, and response to immunotherapy. Initially known for their role as chemoattractants in guiding leukocyte migration,Read More…

30Apr/23
Recombinant Antibody

Scientists Reviewed the Advances, Challenges and Countermeasures in Immunotherapy of Gastrointestinal Tumors

April 30, 2023Cancer Immunotherapy, NewsGastrointestinal Tumor, immunotherapybiorab

The morbidity and mortality of intestinal tumors are among the top malignant tumors, and they are major diseases that seriously threaten people’s health. The prognosis for some patients with gastrointestinal malignancies hasRead More…

12Mar/23

Released! Mechanisms Behind Immune Cells’ Responses to Cancer Cell Mutations

March 12, 2023Cancer Immunotherapy, NewsCancer Immunotherapybiorab

Neoantigens are peptides derived from nonsynonymous mutations in human leukocyte antigens (HLAs) that are recognized by antitumor T cells. The large diversity of HLA alleles and limited clinical samples often narrow scientists’Read More…

22Feb/23

The Ineffectiveness of Cancer Immunotherapy May Be Due to the Lack of Specific Key Immune Cells in Patients

February 22, 2023Cancer ImmunotherapyCancer Immunotherapybiorab

Nowadays, immunotherapy has dramatically changed the care of cancer patients. In the case of patients with advanced melanoma, one of the most lethal cancers of human skin, the 5-year survival rate hasRead More…

02Jan/23

Scientists Discovered the Key Molecule Triggering Cancer Metastasis

January 2, 2023Cancer Immunotherapy, NewsCancer Immunotherapybiorab

Many cancer cells never leave their original tumor tissue. Some cancer cells have evolved the ability to migrate to other tissues, but they will become dormant once they are unable to formRead More…

Posts navigation

  • 1
  • 2
  • Next »

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • CD73 Inhibition: A Promising Strategy for Overcoming Immune Evasion in Colorectal Cancer
  • A Breakthrough in Influenza Defense: Discovering Antibodies for Broad-Spectrum Protection
  • Discovery of Highly Neutralizing Human Antibodies Targeting Pseudomonas aeruginosa for Treatment of Drug-Resistant Infections
  • Two New Strategies Targeting Siglec-7 Show Promise in Treating Ovarian Cancer
  • Researchers Revealed the Feasibility and Clinical Prospects of Targeting SLC7A11 for the Treatment of Osteosarcoma

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News